


# CLAIMS

1. A compound represented by the general formula (I):



5 wherein R<sup>1</sup> is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkenyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, C3-C8 cycloalkyl, C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group A, or phenyl optionally substituted with one or two substituent(s) selected from substituent group A;

R<sup>5</sup> is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

15 R<sup>6</sup> is a hydrogen atom, a halogen atom, or C1-C3 alkyl;

R<sup>7</sup> is a halogen atom or C1-C3 alkyl;

R<sup>8</sup> is a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R<sup>9</sup> is a hydrogen atom or C1-C6 alkyl; or

20 R<sup>1</sup> and R<sup>5</sup> are taken together with the adjacent carbon atoms may form a 5 to 8 membered ring which may contain a heteroatom and /or an unsaturated bond, wherein the ring may be substituted with one or two C1-C8 alkyl;

provided that when R<sup>2</sup> and R<sup>3</sup> are a chlorine atom, R<sup>6</sup> is not a hydrogen atom;

substituent group A consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C12 alkyloxy, C2-C12 alkenyloxy, C2-C12 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy - C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8

alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;

a pharmaceutically acceptable salt, or solvate thereof.

2. A compound of claim 1, wherein both of R<sup>6</sup> and R<sup>7</sup> are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.


3. A compound of claim 1, wherein R<sup>5</sup> is a hydrogen atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

4. A compound of claim 1, wherein R<sup>8</sup> is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

5. A compound of any one of claims 1 to 4, wherein R<sup>2</sup> is C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, or C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group A, a pharmaceutically acceptable salt, or solvate thereof.

6. A compound of any one of claims 1 to 4, wherein R<sup>2</sup> is C1-C12 alkyl optionally substituted with one or two C1-C8 alkyloxy, and both of R<sup>3</sup> and R<sup>4</sup> are a hydrogen atom, a pharmaceutically acceptable salt, or solvate thereof.

7. A compound represented by the general formula (II):



wherein R<sup>A</sup> is a hydrogen atom, C1-C12 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy or (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy;

R<sup>B</sup> is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, C3-C8 cycloalkyl, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group B, phenyl, or naphthyl;

R<sup>C</sup> is a a atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

$R^D$  is a hydrogen atom, halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

$R^6$  and  $R^7$  are each independently halogen atom or C1-C3 alkyl;

$R^8$  is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group B consists of halogen atom, C3-C8 cycloalkyl, C3-C8  
5 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8  
alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy,  
naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8  
alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy,  
haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8  
10 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;

a pharmaceutically acceptable salt, or solvate thereof.

8. A compound of claim 7, wherein both of  $R^6$  and  $R^7$  are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.


9. A compound of claim 7, wherein  $R^8$  is methyl or methyloxy, a pharmaceutically  
15 acceptable salt, or solvate thereof.

10. A compound of claim 7, wherein  $R^C$  is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

11. A compound of any one of claims 7 to 10, wherein  $R^A$  is C1-C8 alkyloxy;  $R^B$  is C1-C11 alkyl optionally substituted with one or two substituent(s) selected from  
20 substituent group B, or C2-C11 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

12. A compound of claim 7, wherein  $R^C$  is fluorine atom or C1-C3 alkyloxy,  $R^D$  is a hydrogen atom or C1-C3 alkyloxy, both of  $R^6$  and  $R^7$  are fluorine atom or chlorine atom,  
25  $R^8$  is methyl or methyloxy,  $R^A$  is C1-C3 alkyloxy,  $R^B$  is C8-C12 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

13. A compound represented by the general formula (III):



wherein  $R^E$  is C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group C, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group C, or C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group C;

Z is straight-chain C1-C4 alkylene optionally substituted with C1-C8 alkyl, which may contain an optionally substituted heteroatom(s) or straight-chain C2-C4 alkenylene optionally substituted with C1-C8 alkyl, which may contain an optionally substituted heteroatom(s)

$R^6$  and  $R^7$  are each independently halogen atom or C1-C3 alkyl;

$R^8$  is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group C consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy; a pharmaceutically acceptable salt, or solvate thereof.

14. A compound of claim 13, wherein both of  $R^6$  and  $R^7$  are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

15. A compound of claim 13, wherein  $R^8$  is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.


16. A compound of claim 13, wherein Z is C1-C4 alkylene, -O-(C1-C3 alkylene)- or -(C1-C3 alkylene)-O-, a pharmaceutically acceptable salt, or solvate thereof.

17. A compound of any one of claims 13 to 16, wherein  $R^E$  is C1-C10 alkyl optionally substituted with one or two substituent(s) selected from substituent group C,

C2-C10 alkynyl optionally substituted with one or two substituent(s) selected from substituent group C, or C1-C10 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group C, a pharmaceutically acceptable salt, or solvate thereof.

18. A compound of claim 13, wherein both of R<sup>6</sup> and R<sup>7</sup> are fluorine atom or chlorine atom, R<sup>8</sup> is methyl or methoxy, R<sup>E</sup> is C1-C8 alkyl optionally substituted with one or two C1-C6 alkyloxy, Z is C1-C2 alkylene, a pharmaceutically acceptable salt, or solvate thereof.

19. A compound represented by the general formula (II-A):



wherein R<sup>C</sup> is a hydrogen atom, a halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R<sup>D</sup> is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R<sup>F</sup> is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkenyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group C, C3-C8 cycloalkyl, or phenyl optionally substituted with one or two substituent(s) selected from substituent group D;

R<sup>6</sup> and R<sup>7</sup> are each independently halogen atom or C1-C3 alkyl;

R<sup>8</sup> is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group D consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;

a pharmaceutically acceptable salt, or solvate thereof.

20. A compound of claim 19, wherein both of R<sup>6</sup> and R<sup>7</sup> are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

21. A compound of claim 19, wherein R<sup>8</sup> is methyl or methoxy, a  
5 pharmaceutically acceptable salt, or solvate thereof.

22. A compound of claim 19, wherein R<sup>C</sup> is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

23. A compound of any one of claims 19 to 22, wherein R<sup>E</sup> is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D,  
10 C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, or C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group D, a pharmaceutically acceptable salt, or solvate thereof.

24. A pharmaceutical composition containing a compound as an active ingredient,  
15 a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 23.

25. A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 23, which is exhibiting thrombopoietin receptor agonism.

26. A platelet production modifier which contains a compound as an active  
20 ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 23.

27. Use of a compound, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 23 for preparation of a pharmaceutical composition for modifying a platelet production.

25 28. A method for modifying a platelet production of a mammal, including a human, which comprises administration to said mammal of a compound, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 23 in a pharmaceutically effective amount.